About CytoSite Bio
CytoSite Bio is a Healthcare company based in United States founded in 2016 by Benjamin Larimer, Jim Jenson, Umar Mahmood, and Eric Wehrengerg Klee. Precision imaging products for immuno-oncology therapy are developed. CytoSite Bio has raised $7.49 million across 4 funding rounds from investors including HHS. Its chief executive, as recorded, is Jim Jenson. CytoSite Bio offers products and services including Granzyme B PET Agent and PET Imaging Protocol. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Diversified. Its competitors include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences; 3 of its 3 listed competitors have raised funding.
Company details
CytoSite Bio was founded in 2016 in the United States and operates in the biotechnology sector focused on immuno-oncology. Precision imaging products are developed to detect active T-cell or NK cell activity through Granzyme B, which targets tumor cell killing by the immune system. These tools enable optimization of patient immunotherapy regimens by providing insights into treatment efficacy. The companys operations center on advancing diagnostic technologies for clinical use.
- Headquarters United States
- Founders Benjamin Larimer, Jim Jenson, Umar Mahmood, Eric Wehrengerg Klee
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website cytositebio.com
- Total Equity Funding$7.49M (USD)
in 4 rounds
- Latest Funding Round$3.05M (USD), Series A
Sep 2020
- Investors
Products & Services of CytoSite Bio
CytoSite Bio offers a comprehensive portfolio of products and services, including Granzyme B PET Agent and PET Imaging Protocol.
PET agent for detecting immune cell activation in cancer immunotherapy monitoring.
Protocol for non-invasive immune response evaluation in clinical trials.
Funding Insights of CytoSite Bio
CytoSite Bio has successfully raised a total of $7.49M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $3.05 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $7.49M
- Total Rounds 4
- Last Round Series A — $3.05M
- First Round $10,760
(Dec 2017)
- Investors Count 1
All 4 funding rounds of CytoSite Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | $3.05M | Series A | – | – | – |
| Sep 2018 | $1.8M | Grant | – | – | |
| Aug 2018 | $4.42M | Series A | – | – | – |
| Dec 2017 | $10,760 | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in CytoSite Bio
CytoSite Bio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for CytoSite Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of CytoSite Bio
4 people are tracked at CytoSite Bio (4 in leadership).
| Name | Role | Group |
|---|---|---|
Benjamin Larimer | Co-Founder | Leadership |
Jim Jenson | Co-Founder & CEO | Leadership |
Umar Mahmood | Co-Founder | Leadership |
Eric Wehrengerg Klee | Co-Founder | Leadership |
Complete people profiles for CytoSite Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of CytoSite Bio
3 dated milestones of CytoSite Bio across 4 years, from founding to its latest funding, stage changes and deals.
- Founded CytoSite Bio is founded.
- Funding First funding round of $11K.
- Funding Latest funding round, Series A, of $3.0M.
Competitors of CytoSite Bio
CytoSite Bio has 3 listed competitors in our database, 3 of them funded. They include Denali Therapeutics, Poseida Therapeutics and Castle Biosciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| denalitherapeutics.com | 2015 | San Francisco, United States | $347M | 377 | Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's. | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| cernostics.com | 2008 | Pittsburgh, United States | $14.18M | 16 | Precision diagnostic and prognostic tests are developed by Castle Biosciences. |
Detailed competitors of CytoSite Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of CytoSite Bio
The website of CytoSite Bio (cytositebio.com) receives about 1.3K visits a month.
- Monthly visits1.3K
▲ 84.6% vs previous month
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as CytoSite Bio (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Cytosite Bio
Complete news archive for CytoSite Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CytoSite Bio
CytoSite Bio was founded in 2016 and raised its 1st funding round 1 year after it was founded.
CytoSite Bio is headquartered in United States.
Jim Jenson is the CEO of CytoSite Bio, as recorded in our data. They have also founded this company.
CytoSite Bio is a funded company, having raised a total of $7.49M across 4 funding rounds to date. The company's 1st funding round was a Seed of $10.76K, raised on Dec 2017.
CytoSite Bio was founded in 2016 in the United States and operates in the biotechnology sector focused on immuno-oncology. Precision imaging products are developed to detect active T-cell or NK cell activity through Granzyme B, which targets tumor cell killing by the immune system. These tools enable optimization of patient immunotherapy regimens by providing insights into treatment efficacy. The companys operations center on advancing diagnostic technologies for clinical use.
CytoSite Bio's top competitors include Poseida Therapeutics, Denali Therapeutics and Castle Biosciences.
CytoSite Bio offers Granzyme B PET Agent and PET Imaging Protocol.
CytoSite Bio has 1 investor. Key investors include HHS.